Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial

ClinicalTrials.gov ID: NCT00475085

Public ClinicalTrials.gov record NCT00475085. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 24, 2026, 6:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Antiemetic drugs, such as granisetron, dexamethasone, prochlorperazine, aprepitant, and palonosetron, may help lessen or prevent nausea. It is not yet known which combination of antiemetic drugs is more effective in preventing nausea caused by chemotherapy. PURPOSE: This randomized phase III trial is comparing different combinations of granisetron, dexamethasone, prochlorperazine, aprepitant, and palonosetron to see how well they work in preventing nausea in patients undergoing chemotherapy for breast cancer.

Study identification

NCT ID: NCT00475085
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Joseph Roscoe; Other
Enrollment: 1,021 participants

Conditions and interventions

Conditions

Nausea

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 2006 (Type not available)
Primary completion: Dec 2012 (Actual)
Completion: Not listed
Last update posted: Nov 10, 2015

Started 2006

United States locations

U.S. sites: 16
U.S. states: 13
U.S. cities: 16

Facility	City	State	ZIP	Site status
MBCCOP - Gulf Coast	Mobile	Alabama	36695	—
CCOP - Central Illinois	Decatur	Illinois	62526	—
CCOP - Wichita	Wichita	Kansas	67214-3882	—
CCOP - Grand Rapids	Grand Rapids	Michigan	49503	—
CCOP - Kalamazoo	Kalamazoo	Michigan	49007-3731	—
CCOP - Metro-Minnesota	Saint Louis Park	Minnesota	55416	—
CCOP - Kansas City	Kansas City	Missouri	64131	—
CCOP - Nevada Cancer Research Foundation	Las Vegas	Nevada	89106	—
CCOP - Hematology-Oncology Associates of Central New York	East Syracuse	New York	13057	—
CCOP - North Shore University Hospital	Manhassett	New York	11030	—
CCOP - Southeast Cancer Control Consortium	Goldsboro	North Carolina	27534-9479	—
CCOP - Columbus	Columbus	Ohio	43215	—
CCOP - Dayton	Dayton	Ohio	45429	—
CCOP - Greenville	Greenville	South Carolina	29615	—
CCOP - Northwest	Tacoma	Washington	98405-0986	—
CCOP - Marshfield Clinic Research Foundation	Marshfield	Wisconsin	54449	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00475085, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 10, 2015 · Synced Oct 24, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00475085 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →